|
CN111377917A
|
|
Heterocyclic compound, intermediate, preparation method and application thereof
|
|
CN110441460A
|
|
Minigene toxic impurities detection method in a kind of voriconazole
|
|
CN111825675A
|
|
ROCK inhibitor and preparation method and application thereof
|
|
CN109970725A
|
|
The preparation method of posaconazole
|
|
CN111434653A
|
|
Triazole compound and preparation method and application thereof
|
|
CN111434655A
|
|
Lysophosphatidic acid receptor antagonists and process for their preparation
|
|
CN110237071A
|
|
Pharmaceutical preparation and its application
|
|
CN110237072A
|
|
The preparation method of pharmaceutical composition
|
|
CN109513092A
|
|
Intubation conduit, administered by infusion device and animal test model in zoopery
|
|
CN109498633A
|
|
The medical usage of saccharide compound
|
|
CN109316601A
|
|
Medical composition and its use
|
|
CN109316451A
|
|
The oral solid formulation for treating hypertension and related disease
|
|
CN107661302A
|
|
A kind of oral solid formulation and its application
|
|
CN109305965A
|
|
Benzimidizole derivatives preparation and analysis method
|
|
CN107602546A
|
|
Crystal formation of compound and preparation method thereof, composition and application
|
|
CN107033186A
|
|
Posaconazole derivative, its pharmaceutical composition and purposes
|
|
CN112110909A
|
|
Compound, preparation method, composition and application thereof
|
|
CN107028954A
|
|
Ornithine aspartate is preparing the purposes in preventing and treating fatty liver medicament
|
